E
Ensysce Biosciences
Focuses on developing drugs to treat pain and prevent opioid abuse
About Ensysce Biosciences
Ensysce Biosciences is a pioneering pharmaceutical company focused on addressing the opioid abuse and overdose crisis through innovative drug development. Operating in the biotech and pharmaceutical markets, Ensysce serves healthcare providers, patients, and regulatory bodies by developing safer opioid analgesics. The company's core business model revolves around its proprietary prodrug technology, which modifies the drug substance at a chemical level to prevent abuse and overdose. This approach differentiates Ensysce from traditional methods that alter the drug formulation, which have proven ineffective. Ensysce generates revenue through the development and commercialization of its unique opioid products, aiming to launch the first new class of opioid analgesics in decades. The company leverages its expert team, including leaders in emergency medicine and toxicology, to bring these groundbreaking drugs to market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2008
- Headquarters
- San Diego, United States
- Listing
- IPO 2018
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Institutes of Health
National Institute on Drug Abuse (NIDA)
Series A1 investor entered at this stage
Texas Economic Development Corporation
Series B and later1 investor entered at this stage
Global Emerging Markets
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ensysce Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ensysce Biosciences on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.